Ticker brief · 2026-08-16
BBIO BRIDGEBIO PHARMA INC
Attruby execution drives rerating despite debt and KKR supply
Consumer, Non-cyclical · Biotechnology
Lean: bullishlast close
$76.60
1 day
-2.6%
14 days
-4.1%
mkt cap
$15.1B
signals 14d
30
authors 14d
8
crowd 14d
+0.2σ
The evidence leans bullish: credible voices broadly validate Attruby execution, product differentiation, and pipeline depth, while one credible holder supplies the principal debt critique. The most important late-week shift was KKR monetizing 5 million shares at $78, introducing supply after multiple $104–$110 sell-side targets. The oversubscribed, non-dilutive block suggests demand remains healthy, but leverage and secondary supply constrain near-term trade structure.
BULL CAMP
Attruby's $222.4M Q2 performance, improving first-line share, and favorable clinical differentiation support a durable commercial ramp. Multiple regulatory milestones, four potential blockbusters, and higher sell-side targets broaden the thesis beyond one product.
Key voices@semodoughMEDIUM-HIGHC-3.01@Biotech2k1MEDIUM-HIGHA+1.02@PersimmonTIMEDIUM-HIGHA-0.57@adamfeuersteinHIGHA+1.41@FiercePharmaMEDIUM-HIGHB-1.09
“Q2 revenue reached $243.7M, including $222.4M of Attruby U.S. net product revenue.”— @semodough · tweet ↗
BEAR / SKEPTIC
BBIO's roughly $3.5B debt load and estimated 21% dilution could overwhelm otherwise strong commercial and pipeline execution. KKR's 5 million-share sale adds a nearer-term supply overhang, although it does not raise new capital.
Key voices“Strong sales and pipeline potential remain offset by heavy convertible debt and estimated 21% dilution.”— @Biotech2k1 · tweet ↗
Hypotheses11direction · basis · magnitude · supporters — NEW = first seen this week
▲Attruby's $222.4M Q2 sales and rising patient additions demonstrate a stronger-than-expected commercial launch with continuing growth momentum.
@semodoughMEDIUM-HIGHC-3.013s@AponiaAnalyticsLOW-MEDIUMB+4.911s · insight@EmmanuelInvestLOW-MEDIUMC-1.111s@PersimmonTIMEDIUM-HIGHA-0.572s · insight@FwdQuarterLOW-MEDIUMC1s@adamfeuersteinHIGHA+1.411s · insight
▲Attruby's clinical differentiation, adoption, and pricing support preferred first-line use and a path toward blockbuster status in ATTR.
@semodoughMEDIUM-HIGHC-3.014s@FiercePharmaMEDIUM-HIGHB-1.091s
▲Upcoming ESC data should reinforce Attruby as preferred first-line therapy and could produce an approximately 5% BBIO move.
@semodoughMEDIUM-HIGHC-3.011s
▲BBIO's four potential blockbusters and bullish 2030 model support substantial value beyond the current Attruby commercial ramp.
@semodoughMEDIUM-HIGHC-3.012s@Biotech2k1MEDIUM-HIGHA+1.021s · insight
▲BBIO can reach profitability in 2028 and use future cash generation to repay debt, making leverage manageable over time.
@semodoughMEDIUM-HIGHC-3.012s
▼Roughly $3.5B of debt and estimated 21% dilution create material downside risk despite strong sales and pipeline potential.
@Biotech2k1MEDIUM-HIGHA+1.023s · insight
▼KKR's 5 million-share sale at $78 creates a near-term supply overhang despite being oversubscribed and non-dilutive.
@AponiaAnalyticsLOW-MEDIUMB+4.912s · insight@BioStocksMEDIUM-HIGHC-3.021s
▲BBIO appears undervalued relative to biotech peers based on current sales, commercial potential, and the quality of its assets.
@Biotech2k1MEDIUM-HIGHA+1.021s · insight@bioinvestor24MEDIUM-HIGHA-0.451s · insight
▲Submitted NDAs, priority review, and three expected approvals within 6–9 months create a dense regulatory catalyst sequence.
@semodoughMEDIUM-HIGHC-3.013s@FwdQuarterLOW-MEDIUMC1s
▲Broad sell-side endorsement, including $104–$110 targets and multiple Overweight ratings, supports a higher near-term valuation range.
@semodoughMEDIUM-HIGHC-3.016s@Quantumup1MEDIUMC2s
▼The rapid Attruby ramp and $1B financing may strain BBIO's ability to execute the launch effectively.
@AponiaAnalyticsLOW-MEDIUMB+4.911s · insight
Direct calls1authors taking explicit directional positions
@Biotech2k1MEDIUM-HIGHA+1.02
Add BBIO on any earnings-driven selloff.
Sellside activity8
BofA pt_raise PT 104Reiterated Buy based on growth and declining regulatory risk.
Truist pt_raise PT 107Highlighted improving Attruby market share.
JPMorgan pt_raise PT 110Expects three additional approvals within 6–9 months.
Jefferies noteExpects ESC data to support preferred first-line use and drive a 5% BBIO move.
Wells Fargo notePrefers BBIO to ALNY given unfavorable ALNY risk-reward.
Piper pt_raiseRaised its BBIO target and reiterated Overweight.
Wells Fargo pt_raiseRaised its BBIO target and reiterated Overweight.
Cantor reiterate PT 110Reiterated Overweight and designated BBIO its top pick.
News / data points5discrete events + data quoted by authors
@semodoughMEDIUM-HIGHC-3.01
BBIO reported $243.7M Q2 revenue, including $222.4M of Attruby U.S. net product revenue.
@BioStocksMEDIUM-HIGHC-3.02
KKR sold 5m shares in a $390m offering at $78, reducing its BBIO stake from 7.3% to 4.7%.
@AponiaAnalyticsLOW-MEDIUMB+4.91
The KKR secondary block comprised 5 million BBIO shares and was oversubscribed.
@semodoughMEDIUM-HIGHC-3.01
BBIO reported priority review, NDA submissions, and multiple clinical-program milestones.
@semodoughMEDIUM-HIGHC-3.01
A bullish 2030 analyst model projects $6B revenue and $13 EPS.
Position disclosures3skin in the game
@Biotech2k1MEDIUM-HIGHA+1.02
Core BBIO long holding.
@Biotech2k1MEDIUM-HIGHA+1.02
Reported an investment gain exceeding 120%.
@Biotech2k1MEDIUM-HIGHA+1.02
Included BBIO within a disclosed weighted biotech portfolio.
Desk readconvergence assessment
Views converge around strong Attruby execution and a deep pipeline, but disagree sharply on whether roughly $3.5B of debt and estimated 21% dilution negate that upside; notably, the principal bull and bear arguments both come from credible authors. The most prolific bull, semodough, has a -2.33 trader score and registry grade C, reducing the value of sheer message volume, while the debt critique comes from an A-grade author with a positive 1.22 score. Sustained Attruby share gains, supportive ESC data, and visible deleveraging would strengthen the bull case; launch slippage or recurring shareholder supply would shift the balance, and prior book hypotheses remain unscored.
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 49% mid · 34 pctile own 1y | IV/HV 1.33× (as of 2026-08-10) |
| Skew — 25Δ RR 30d | -0.126 2 pctile own 1y | puts bid vs calls (downside bid) |
| Net dealer OI (NDOI) | +1.63 normal | 5-session Δ +1.13 (as of 2026-07-09) |
| OI alarm | quiet | last alarm 2024-09-25 (z=2.5) |
Sentiment — last 14 days
daily mean sentiment, 2026-08-15 → 2026-08-28 · now +0.45 (−1 bearish … +1 bullish)
Who spoke8
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @semodough | C | -3.01 | 14 | +0.39 |
| @Biotech2k1 | A | +1.02 | 6 | +0.68 |
| @PersimmonTI | A | -0.57 | 4 | +0.35 |
| @OzmosiHealth | C | · | 2 | +0.10 |
| @AponiaAnalytics | B | +4.91 | 1 | -0.20 |
| @MarketMaestro1 | C | -2.46 | 1 | -0.40 |
| @CrweWorld | C | · | 1 | +0.20 |
| @adamfeuerstein | A | +1.41 | 1 | +0.18 |
Recent signals30of 30 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-28 | @Biotech2k1 | +0.65 | Calls four biotech stocks materially undervalued versus explicit fair values | — | tweet ↗ |
| 2026-08-28 | @Biotech2k1 | +0.65 | Build selected winners toward 10% positions on pullbacks — Plans to increase selected portfolio winners to 10% weights during pullbacks | — | tweet ↗ |
| 2026-08-28 | @semodough | +0.55 | Promotes a discussion of Attruby's positioning and a path to over $3B in peak revenue. | — | tweet ↗ |
| 2026-08-28 | @PersimmonTI | +0.45 | Argues stabilizer differences make ALNY's AMVUTTRA and next-generation silencer outlook worse. | — | tweet ↗ |
| 2026-08-28 | @semodough | +0.50 | Highlights clinical separation as early as three months for first-line stabilizer treatment. | — | tweet ↗ |
| 2026-08-28 | @semodough | +0.40 | Reports Wells Fargo's $102 BBIO target and positive view of Attruby's treatment positioning. | — | tweet ↗ |
| 2026-08-28 | @semodough | +0.20 | Cites Wells Fargo's view that CARDIO-TTRansform data may require modification of ALNY's TRITON trial. | — | tweet ↗ |
| 2026-08-28 | @adamfeuerstein | +0.18 | Provides subgroup cardiovascular event-rate ratios from a study relevant to four amyloidosis drug companies. | — | tweet ↗ |
| 2026-08-28 | @semodough | +0.45 | Highlights apparent treatment separation for BBIO as early as three months. | — | tweet ↗ |
| 2026-08-27 | @semodough | +0.45 | Author expects BBIO to be a major beneficiary of the upcoming ESC26 event. | -2.6% | tweet ↗ |
| 2026-08-27 | @Biotech2k1 | +0.60 | Discloses a COGT purchase and explicit current/target portfolio weights for four biotech holdings. | -2.6% | tweet ↗ |
| 2026-08-26 | @OzmosiHealth | +0.10 | BridgeBio dosed the first participant in a Phase 3b/4 study. | -3.5% | tweet ↗ |
| 2026-08-26 | @CrweWorld | +0.20 | BridgeBio announces the first participant dosed in a Phase 3b/4 long-term acoramidis study. | -3.5% | tweet ↗ |
| 2026-08-26 | @Biotech2k1 | +0.80 | Plans to build core biotech names toward 10% each and add IDYA and COGT at good values. — Explicit portfolio-building plan specifies target weights and value-dependent additions. | -3.5% | tweet ↗ |
| 2026-08-25 | @Biotech2k1 | +0.80 | Added to INSM, PTGX, BBIO and PRAX for their long-term mega-cap pipeline potential. — Explicit additions are backed by pipeline upside and relative valuation. | -4.7% | tweet ↗ |
| 2026-08-24 | @OzmosiHealth | +0.10 | BridgeBio will present new acoramidis extension-analysis data at ESC Congress 2026. | -5.5% | tweet ↗ |
| 2026-08-24 | @MarketMaestro1 | -0.40 | BBIO has failed to break its correction band and trigger a renewed rally. | -5.5% | tweet ↗ |
| 2026-08-24 | @PersimmonTI | +0.40 | Author reacts positively to an apparent mortality-benefit result, but the linked evidence is unavailable. | -5.5% | tweet ↗ |
| 2026-08-23 | @semodough | +0.00 | Flags four biotech names for a busy upcoming ESC26 week without stating a directional view. | -6.0% | tweet ↗ |
| 2026-08-23 | @PersimmonTI | +0.75 | Predicts BBIO could become the next VRTX if it remains independent. | -6.0% | tweet ↗ |
| 2026-08-21 | @semodough | +0.00 | Announces a Cantor fireside chat on CARDIO-TTRansform data for August 28. | -6.0% | tweet ↗ |
| 2026-08-21 | @semodough | +0.40 | BofA maintains Buy and a $104 target on BBIO after KOL discussions ahead of ESC. | -6.0% | tweet ↗ |
| 2026-08-19 | @Biotech2k1 | +0.60 | Discloses finalized core portfolio holdings and plans to sell positions that failed analysis into rallies | -8.8% | tweet ↗ |
| 2026-08-18 | @PersimmonTI | -0.20 | Details KKR's completed secondary sale of five million BBIO shares at $77.415 net per share. | -7.7% | tweet ↗ |
| 2026-08-18 | @semodough | +0.70 | Argues Attruby models are too low given a potential $8–9 billion market opportunity. | -7.7% | tweet ↗ |
| 2026-08-18 | @semodough | +0.45 | Cites strong treatment-naive share and management's expectation for Attruby to capture about 40% of its market. | -7.7% | tweet ↗ |
| 2026-08-18 | @semodough | +0.40 | Cowen sets a $110 BBIO target, citing Attruby share gains and an undervalued pipeline. | -7.7% | tweet ↗ |
| 2026-08-16 | @semodough | +0.80 | Cites KOL evidence favoring Attruby over Pfizer's therapy on share, potency and clinical improvement. | -4.1% | tweet ↗ |
| 2026-08-16 | @semodough | +0.20 | Reports a KOL's TTR-CM patient mix, prevalence, diagnostic trends and 20% annual practice growth. | -4.1% | tweet ↗ |
| 2026-08-15 | @AponiaAnalytics | -0.20 | KKR is monetizing five million BBIO shares without a new capital raise | -4.1% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.